| Literature DB >> 21040694 |
Kazi Mizanur Rahman1, Shams El Arifeen, K Zaman, Mahbubur Rahman, Rubhana Raqib, Mohammad Yunus, Nazma Begum, Md Shaheenul Islam, Badrul Munir Sohel, Muntasirur Rahman, Malabi Venkatesan, Thomas L Hale, Daniel W Isenbarger, Philippe J Sansonetti, Robert E Black, Abdullah H Baqui.
Abstract
In double-blind trials in Bangladesh, 88 adults, and 79 children (8-10 years) were randomized to receive either a single oral dose of 1 × 10(4), 1 × 10(5) or 1 × 10(6)CFU of SC602 (a live, attenuated Shigella flexneri 2a strain vaccine) or placebo. In the adult outpatient 1 × 10(6) CFU group, severe joint pain and body aches were reported by one and two vaccinees respectively. In the adult inpatient trial, SC602 was isolated from 3 volunteers, pre-vaccination antibody titers were high, and fourfold increases in serum IgG anti-LPS responses were observed in 2 of 5 subjects of the 1 × 10(6)CFU group. None of the volunteers developed diarrhea. Overall, SC602 was found to be associated with minimal vaccine shedding, minimal reactogenicity, no transmission risk, and low immune stimulation. Copyright ÂEntities:
Mesh：
Substances：
Year: 2010 PMID： 21040694 DOI： 10.1016/j.vaccine.2010.10.035
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641